Clinical significance of different types ofp53gene alteration in surgically treated prostate cancer

Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis

(2013) W Hanel et al.   CELL DEATH AND DIFFERENTIATION

Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressiveERGfusion-positive prostate cancers

(2013) Antje Krohn et al.   JOURNAL OF PATHOLOGY

Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions

(2013) Martina Kluth et al.   MODERN PATHOLOGY

Genomic Deletion of PTEN Is Associated with Tumor Progression and Early PSA Recurrence in ERG Fusion-Positive and Fusion-Negative Prostate Cancer

(2012) Antje Krohn et al.   AMERICAN JOURNAL OF PATHOLOGY

Mutant p53 Aggregates into Prion-like Amyloid Oligomers and Fibrils

(2012) Ana P. D. Ano Bom et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer

(2012) Christopher E Barbieri et al.   NATURE GENETICS

New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs

(2012) Bryan A. Gibson et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis

(2012) Bernard Leroy et al.   NUCLEIC ACIDS RESEARCH

The gain of function of p53 cancer mutant in promoting mammary tumorigenesis

(2012) X Lu et al.   ONCOGENE

Mechanistic Rationale for Inhibition of Poly(ADP-Ribose) Polymerase in ETS Gene Fusion-Positive Prostate Cancer

(2011) J. Chad Brenner et al.   CANCER CELL

ERG Status Is Unrelated to PSA Recurrence in Radically Operated Prostate Cancer in the Absence of Antihormonal Therapy

(2011) Sarah Minner et al.   CLINICAL CANCER RESEARCH

Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis

(2011) Anna Yemelyanova et al.   MODERN PATHOLOGY

A continuum model for tumour suppression

(2011) Alice H. Berger et al.   NATURE

Low Level Her2 Overexpression Is Associated with Rapid Tumor Cell Proliferation and Poor Prognosis in Prostate Cancer

(2010) S. Minner et al.   CLINICAL CANCER RESEARCH

Expression of Bcl-2, p53, and MDM2 in Localized Prostate Cancer With Respect to the Outcome of Radical Radiotherapy Dose Escalation

(2010) Roy Vergis et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

p53 immunochemistry is an independent prognostic marker for outcome in conservatively treated prostate cancer

(2009) Sak Kudahetti et al.   BJU INTERNATIONAL

Chromosome 8p Deletions and 8q Gains are Associated with Tumor Progression and Poor Prognosis in Prostate Cancer

(2009) A. T. El Gammal et al.   CLINICAL CANCER RESEARCH

ETS rearrangements and prostate cancer initiation

(2009) Brett S. Carver et al.   NATURE

Chromosomal imbalances, loss of heterozygosity, and immunohistochemical expression of TP53, RB1, and PTEN in intraductal cancer, intraepithelial neoplasia, and invasive adenocarcinoma of the prostate

(2008) Olaf Bettendorf et al.   GENES CHROMOSOMES & CANCER

KLF6 and TP53 mutations are a rare event in prostate cancer: distinguishing between Taq polymerase artifacts and true mutations

(2008) Laia Agell et al.   MODERN PATHOLOGY

Clinical significance of p53 alterations in surgically treated prostate cancers

(2008) Thorsten Schlomm et al.   MODERN PATHOLOGY

Role of the TMPRSS2-ERG Gene Fusion in Prostate Cancer

(2008) Scott A. Tomlins et al.   NEOPLASIA